News

Why Corbus Pharmaceuticals Holdings Inc Shares Skyrocketed Today

Corbus Pharmaceuticals (NASDAQ: CRBP) is up 29% at 1:18 p.m. EDT after an analyst at Cantor Fitzgerald initiated coverage of the biotech with a buy rating.
There’s plenty to learn about Corbus Pharmaceuticals. The biotech only has one drug, resunab, but it’s testing the anti-inflammatory drug in multiple indications: cystic fibrosis, systemic sclerosis, dermatomyositis, and lupus. Read more >>

AOBiome Announces First-of-its Kind Trial of Live Topical Bacterial Treatment for Acne

Leading skin microbiome company AOBiome announced today the launch of its Phase 2B trial using its first-in-class live bacteria to treat acne. Phase 2B marks the advancement from the company’s successful Phase 1B/2A dose-ranging safety study, which resulted in no serious adverse events and no difference in adverse events between treatment and vehicle groups. Read more >>

Congratulations to Boston Harbor Angels on Being Named “BUILD Friend of the Year” as Part of the 5-Year Anniversary BUILDFest Gala

BUILD will award Mic Williams and Boston Harbor Angels the “BUILD Friend of the Year Award” as part of their 5-Year Anniversary BUILDFest Gala, which will be held on Wednesday October 19th from 5:30-9:30 pm at the Boston Convention Center.
BUILD and Boston Harbor Angels have partnered and are very happy to be able to bring more resources to help at-risk youth. Read more >>

Siamab Therapeutics Presents Promising Preclinical Data at 2016 AACR Ovarian Cancer Research Symposium

Siamab Therapeutics, Inc., a biotechnology company developing novel cancer immunotherapies, today announced new pre-clinical data that showed its novel ST1 antibody drug conjugates (ADCs) target chemoresistant ovarian cancer cells and demonstrate strong efficacy in ovarian cancer models. These data were presented at the American Association for Cancer Research (AACR)’s 11th Biennial Ovarian Cancer Research Symposium 2016 in Seattle, Wash., on Monday, Sept. 12, 2016. Read more >>

Allergan Acquires Gene Therapy Company RetroSense Therapeutics Adding First-In-Class Technology to Company’s Innovative Eye Care Pipeline

llergan plc (NYSE: AGN), a leading global pharmaceutical company, and RetroSense Therapeutics LLC, a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness, today announced that Allergan has acquired substantially all of the assets of RetroSense in an all-cash transaction. Under the terms of the transaction, Allergan has paid RetroSense a $60 million upfront payment, and has agreed to potential regulatory and commercialization milestone payments related to its lead […]

Martin Lowenthal of The Bulfinch Group Earns Retirement Income Certified Professional Designation

Martin Lowenthal, MSIM, CLU®, ChFC®, RICP®, CLTC®, a Financial Representative of The Bulfinch Group, has passed the rigorous American College certification of Retirement Income Certified Professional, an advanced designation. Martin is only the second Bulfinch Group associate to have earned this prestigious designation.
This new designation from The American College creates strategies for Advisors who are focused on the needs of the thousands of Americans reaching age 65 who need guidance in obtaining sustainable retirement income. “Martin Lowenthal’s accomplishment in […]

Boston Harbor Angels Inc. Appoints New CEO

Boston Leading Angel Investor group Strengthens Resources
Ziad Moukheiber
Boston, MA Boston Harbor Angels Inc announced the appointment of Ziad H. Moukheiber as BHA’s Chief Executive Officer.
“Ziad will be a great asset to our angel group. He has experience in entrepreneurship with his previous company SilverSword LLC [Acquired by NSk Inc.] he has demonstrated a unique ability to identify and nurture early stage companies with the potential to scale. Ziad has extensive customer service experience that will ensure that our members […]